Citations

A nonlinear model of the human aural system is proposed. Utilizing a homomorphic transformation, the model is implemented in a digital computer and accounts for the Fletcher critical bands in hearing, the nonlinear relationship between input sound intensity and perceived loudness known as recruitment, as well as the thresholds of audibility and the maximum tolerance threshold. The transformed or output signal domain is identified as a perceptual space. It is shown that the model can be used to reproduce the Fletcher Munson equal loudness contours for normal hearing populations. Modification of easily measured parameters results in the generation of equal loudness contours for hearing impaired individuals. Through a combination of the forward homomorphic transformation for normal hearing to the perceptual domain and the inverse mapping utilizing parameters of a hearing impaired individual, it is shown that hearing intelligibility is dramatically improved. It is postulated that signal processing performed in the perceptual domain will produce results more pleasing and intelligible to the listener. Results of auditory testing utilizing the proposed model for both normal and hearing impaired populations are presented. Speech intelligibility scores are shown to increase by more than 40% (i.e., from 40% to over 80%) over preprocessed scores under headphones for hearing impaired subjects used in these tests.

Abstract Purpose: Most colorectal cancers that have high levels of microsatellite instability (MSI-H) show loss of immunohistochemical expression of proteins that participate in the DNA mismatch repair process, most often involving MLH1 and MSH2. Less commonly, a third DNA mismatch repair protein, MSH6, may also be lost as the primary event. Rarely, tumors with MSI-H show normal expression of these three proteins. The genetic deficiency leading to the MSI-H phenotype in such cases is unknown. PMS2 is another member of the DNA mismatch repair complex. Its expression is generally lost in tumors with MLH1 loss of expression. Rarely, there is selective loss of PMS2 expression. We sought to describe the frequency and clinical correlates of selective loss of expression of PMS2 with the MSI-H tumor phenotype. Experimental Design: Two thousand seven hundred nineteen colorectal cancers from both clinic- and research-based ascertainment were studied. Tumor MSI testing and immunohistochemistry for MLH1, MSH2, MSH6, and PMS2 were conducted. Medical records were abstracted for age at diagnosis, gender, colorectal cancer site, and family history. Results: Five hundred thirty-five of the 2,719 tumors were MSI-H. Of these, 93% showed loss of expression of MLH1, MSH2, and/or MSH6. Thirty-eight showed normal expression for these proteins. PMS2 immunohistochemical staining was successful in 32 of 38 of these tumors. Of the 32, 23 showed selective loss of expression of PMS2. This was associated with young age of diagnosis and right-sided location but not with a striking family history of cancer. Conclusions: Overall, 97% of the MSI-H tumors showed loss of expression for one or more of these four mismatch repair proteins. Selective loss of expression of PMS2 was present in 72% of cases in which colorectal cancers had an MSI-H phenotype but no alteration of expression of MLH1, MSH2, and MSH6. The underlying mechanism involved cannot be determined from this study but could involve point mutations in other DNA mismatch repair genes with retention of immunohistochemical expression, somatic inactivation of PMS2, or germ line mutation of PMS2.